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Introduction
For many years, it was thought that the function of the large 
intestine was to reabsorb water and salt and remove unused 
food debris. It is now evident that the intestinal microbiota 
plays an important, if not crucial, role in the metabolism of 
chemical compounds found within foods. The large num-
ber of bacteria inhabiting the large intestine forms a highly 
complex ecosystem called the ‘intestinal microbiome’. The 
word ‘microbiome’ was first introduced in 2001 to define 
the collective genomes of the microbiota [1]. In 2007, the 
‘human microbiome project’ was launched with the aim of 
collecting and integrating genomic information from many 
diverse human microbiomes and examining the relation-
ship between changes in the human microbiome and vari-
ous diseases [2, 3]. Growing scientific interest in the com-
position of the microbiome and its impact on human health 
has led to the initiation of many similar projects all over the 
world. The NIH Human Microbiome Project (2007, USA) 
aimed to characterize the influence of the microbiota on 
the human body and to correlate changes in these micro-
bial populations with human health. The Irish ELDERMET 
Project (2007–2013) focused on characterization of the 
fecal microbiota associated with aging and aimed to cor-
relate the composition, diversity and metabolic potential 
of the fecal microbial metagenome with health, diet and 
lifestyle. MetaHIT (metagenomics of the human intesti-
nal tract, 2008–2011) was a European project focused on 
assessing the role of the microbiota in inflammatory bowel 
disease and obesity. The French project Microbes (human 
intestinal microbiome in obesity and nutritional transition, 
2008–2010) sought to identify metagenomic signatures 
that characterize the relationship between the intestinal 
microbiome and the nutritional and metabolic status of 
the host. The interactions between intestinal microbes and 
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host health were also evaluated by the Australian jumpstart 
human microbiome project (2009) and Canadian Human 
Microbiome Initiative (2009). Still in progress is the 
Korean Microbiome Diversity using Korean Twin Cohort 
Project (2010–2015) that aims to determine the microbi-
omes on various epithelial sites of the human body using 
the Korean twin cohort and to investigate the relationship 
between the human microbiome and disease.
The aim of this article is to review recent studies on fac-
tors affecting the composition of the human gut microbiota 
with a particular emphasis on polyphenolic compounds. 
The manuscript presents a compilation of the knowledge 
on functional aspects of the normal gut microbiota from 
two perspectives: (1) the role of particular microbial spe-
cies in the metabolism of polyphenols and (2) a detailed 
insight into the role of biotransformation of polyphenols in 
relation to their beneficial functions on health.
Microbial diversity of the human gut microbiota
The human gut is colonized by an enormous number of 
microorganisms, mainly bacteria. It is estimated that the 
microbiota of a human adult is composed of ~1014 bacte-
rial cells, which is ten times more than the total number of 
human cells [4]. The metabolic capacity of the intestinal 
microbiome is approximately 100-fold greater than that 
of the human liver. This is a result of the great diversity 
of bacterial species forming the population, and hence the 
large number of genes which they contain [4].
The process of gut colonization starts immediately after 
birth. The infant’s microbiota initially shows instability and 
low diversity, evolving into a more stable adult-type micro-
biota after the first 2–4 years of life. Its final composition 
depends on environmental factors. According to Sakata 
et al. [5] in the first week of human life enterobacteria, 
streptococci, enterococci and staphylococci are already pre-
sent in the infant’s gut while anaerobes such as bifidobac-
teria, lactobacilli and Bacteroides spp. are not. The gradual 
consumption of oxygen in the intestine by aerobic microor-
ganisms provides conditions for the settlement of anaero-
bic bacteria. Breastfeeding is a significant factor in the 
determination of the neonatal gut microbiota. In full-time 
breastfed babies (1 month old), bifidobacteria constituted 
a predominant group in the feces, while in formula-fed 
infants, although bifidobacteria were also the predominant 
species, other bacteria such as enterobacteria, enterococci, 
lactobacilli, clostridia and Bacteroides spp. were present 
in significantly higher numbers compared with breastfed 
infants [6, 7].
Initial colonization of the intestine does not appear to be 
random but rather ‘pre-programmed’. Although host genet-
ics can predict microbial composition to an extent, several 
extrinsic factors (mode of infant delivery, antibiotic expo-
sure, neonatal nutrition, adult nutrition, stress, age, degree 
of hygiene, bacterial infections) contribute to the develop-
ment of an individual’s unique microbial composition and 
as a result, susceptibility to several diseases [8, 9]. It has 
been shown that infants born vaginally acquire their own 
mother’s vaginal and intestinal flora (dominated by Lacto-
bacillus, Prevotella, Atopobium or Sneathia spp.) and have 
higher levels of Clostridium spp, while infants delivered by 
cesarean section have increased levels of skin-associated 
bacteria including Staphylococcus, Corynebacterium and 
Propionibacterium spp. [7, 10, 11].
The microbiota of the human gastrointestinal tract starts 
in the mouth, and the number of viable cells is estimated at 
108–1010 colony-forming units (CFU) of bacteria per gram 
of saliva. As a result of the swallowing reflex, these bacte-
ria are continuously transferred to the subsequent parts of 
the gastrointestinal tract. The number of microorganisms is 
significantly reduced in the stomach (~103 CFU/g gastric 
juice), duodenum and jejunum (102–104 CFU/g content), 
increasing again in the ileum and colon (approximately 
1010 CFU/g content and 1010–1012 CFU/g content, respec-
tively) [12]. The enormous number of microorganisms that 
inhabit the human large intestine (up to 1012 bacteria per 
gram of colonic content) is the highest accumulation of 
microorganisms in the environment that has been reported 
to date [13].
The composition, as well as the ratio of different species 
that form the intestinal microbiome, is very diverse within 
the human population [14]. The composition of the human 
gut ecosystem is influenced by multiple and diverse factors, 
such as age, origin, environment, dietary habits (including 
probiotics) and the application of antibiotics. Hence, each 
individual has his or her own unique profile of microbial 
species, which can be compared to a fingerprint. Owing to 
the multitude of direct and indirect interactions with the 
host organism, the intestinal microbiome is closely linked 
to the health of the host [15, 16].
Evidence from culture-based studies led to the number 
of bacterial species in the human intestinal microbiome 
being estimated at approximately 400–500. However, only 
a small proportion of bacteria can be easily cultivated in 
vitro. Consequently, the major populations identified in 
stool samples were composed of bacteria that can grow 
quickly in classical high-nutrient growth media at meso-
philic temperatures. Moreover, such studies were usu-
ally conducted in anaerobic conditions, whereas some gut 
bacteria prefer microaerophilic growth. Development of 
molecular methods of bacterial diversity assessment has 
enabled these limitations to be overcome. Since the year 
2000, large-scale 16S rRNA or metagenomic studies have 
allowed scientists to improve their knowledge regarding 
the diversity of the human gut microbiome [17, 18]. It is 
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commonly accepted that ~80 % of the bacteria identified by 
molecular tools in the human gut are uncultured and hence 
can be characterized only by metagenomic studies [17, 19]. 
Qin et al. [20] found that there are 1,000–1,150 prevalent 
bacterial species, and each individual harbors at least 160 
species.
There are significant inter-individual differences in the 
bacterial species found in the gastrointestinal tract, and 
these differences are a result of the age, health, diet or geo-
graphical location of the individual. On the basis of 16S 
rRNA analysis of intestinal microbiota samples taken from 
different individuals, it has been shown that, despite the 
great diversity of bacterial species, the majority (98 % of 
all species) belong to only four bacterial phyla: Firmicutes 
(64 %), Bacteroidetes (23 %), Proteobacteria (8 %) and 
Actinobacteria (3 %), whereas other minor taxonomic divi-
sions are quite diverse [4, 21, 22]. It should be emphasized 
that the ratio between these groups is strongly dependent 
on the location within the intestine, and on the ethnicity 
of the host. Firmicutes and Bacteroidetes dominate in the 
large intestine, while in the jejunum Proteobacteria are 
more abundant than Bacteroidetes. In the ileum of Japanese 
adults, no Bacteroidetes were detected, whereas these bac-
teria dominated the microbiota of healthy Swedish women 
[12, 23, 24].
Changes of the intestinal microbiota
Age-related changes
The microbiota composition is not stable over the life of 
an individual. It is natural that the diet of elderly individu-
als changes for many reasons, including loss of sensation 
of taste and smell, tooth loss, and chewing difficulties, or 
due to certain diseases that result in the exclusion of certain 
components from the diet (cholesterol, sugar, salt). Some 
of these age-related microbiota composition changes may 
therefore be attributable to diet. However, composition of 
the intestinal microbiota may also vary in elderly subjects 
independently of diet because of a number of physiological 
and immunological factors, such as reduced functionality 
of the immune system. It has been shown that the micro-
biota associated with elderly individuals is characterized 
by reduced abundance of Ruminococcus and Blautia spp. 
and a diminished abundance of several butyrate produc-
ers, while the number of Escherichia is increased com-
pared with young controls [25]. The ratio of Firmicutes 
over Bacteroidetes (F/B) is one of the parameters known 
to change throughout the lifespan. The ratio is lower in the 
first year of life (0.4), increases in adulthood (10.9), and 
decreases during old age (0.6) [26]. Recently, it has been 
demonstrated that the gut microbiota in adolescent children 
11–18 years of age differs from that of adults, with signifi-
cantly higher abundance of Bifidobacterium and Clostrid-
ium genera [27]. These results indicate that adolescent chil-
dren should be considered a separate age-group in this field 
of research.
It is notable that the ratio of Firmicutes to Bacteroidetes 
is higher in obese than in lean humans. Moreover, this pro-
portion decreases with weight loss on a low-calorie diet 
[28]. This means that in addition to the effect of excess 
calories per se, a high-calorie diet predisposes to obesity 
through microbiota modulation, which manifests by the 
increased F/B ratio. Hence, the F/B ratio may also be con-
sidered a useful biomarker of obesity [29].
Diet-related dysbiosis
A balance between the host immune system and the com-
mensal gut microbiota is crucial for maintaining health. 
If this balance is disturbed (dysbiosis), the host–microbe 
relationship can progress toward disease [14, 30]. Dysbio-
sis can be diet-related [19]. It is now clear that microbes 
present in the human gut are essential for the process of 
digestion in the host. During anaerobic fermentation, their 
metabolism causes a breakdown of indigestible compounds 
such as resistant starch and plant polysaccharides, which 
results in short-chain fatty acid (SCFA) production. Other 
examples of microbe-specific metabolism are the syntheses 
of vitamins and amino acids [14]. In contrast, some com-
pounds present in the diet can modulate the microbiota 
composition, resulting in changes in the metabolic activity 
of intestinal bacteria [31].
Specific diets
The composition of the gut microbiota is susceptible to 
the quality and quantity of ingested carbohydrates that are 
the main carbon and energy source for the microbes. Any 
diet that is either selective or defective with respect to its 
nutrient content will cause the disruption of the delicate 
balance between the host and its intestinal microbiota, 
leading to diet-related dysbiosis. Such a situation may 
subsequently favor the overgrowth of opportunistic patho-
gens and weaken the host defense against infection and 
chronic inflammation, possibly via alterations in mucosal 
immunity.
In studies of the intestinal microbiota in humans with 
celiac disease, the numbers of aerobic Staphylococcus, as 
well as anaerobic Clostridium and Bacteroides, were sig-
nificantly higher (p < 0.05) than in healthy subjects. In 
contrast, the number of Bifidobacteria was slightly higher 
in healthy controls [32]. A gluten-free diet (GFD) is a 
type of diet used for celiac disease treatment. It has been 
shown that a GFD itself could lead to modifications of the 
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composition and immune properties of the gut microbiota. 
In the study of Sanz [33], ten healthy subjects (30.3 years 
old) consumed a GFD for 1 month by replacing gluten-
containing foods that they usually ate with certified gluten-
free foods. Analyses of their fecal microbiota and dietary 
intakes demonstrated that populations of Bifidobacterium 
and Lactobacillus (generally regarded as healthy bacteria) 
decreased, while populations of potentially unfavorable 
bacteria such as Escherichia coli and total Enterobacte-
riaceae increased; this occurred in parallel with reductions 
in the intake of polysaccharides. A diet rich in the fructan-
type resistant starches, especially oligofructose and inulin, 
is known to promote “good” species of colon bacteria [34]. 
Such prebiotics are found in the diet mainly in association 
with wheat, barley and onions [35]. This means that a GFD 
could cause similar, potentially adverse changes in the 
microbiota solely on the basis of a significant reduction in 
fructan intake. Provision of gluten-free but prebiotic-rich 
foods, or diet supplementation with fructan-type prebiotics, 
could help avoid these adverse effects and provide impor-
tant support to the intestinal microbiota of people with 
celiac disease.
Other researchers have focused on differences in the 
fecal microbiota of neonates that were fed either breast 
milk or formula. Many studies have shown that breastfeed-
ing results in the development of an intestinal microflora 
rich in Bifidobacteria and Lactobacillus, while formula-fed 
infants are colonized more often with E. coli, Clostridium 
difficile, members of the Bacteroides fragilis group and 
Lactobacilli [6, 7, 36].
The impact of diet on microbiota composition was also 
examined by De Filippo et al. [29]. They demonstrated that 
the fecal microbiota in a cohort of Italian children was dif-
ferent to that found in children in a rural village in Bur-
kina Faso (BF). BF children showed a significant enrich-
ment in Bacteroidetes and depletion in Firmicutes, with a 
unique abundance of bacteria from the genera Prevotella, 
Treponema and Xylanibacter, known to contain a set of 
bacterial genes for cellulose and xylan hydrolysis, which 
were completely lacking in the Italian children. In addi-
tion, significantly more SCFAs were found in BF than in 
Italian children, whereas Enterobacteriaceae (Shigella 
and Escherichia) were significantly underrepresented. 
The authors hypothesized that the gut microbiota have 
coevolved with the long-term polysaccharide-rich diet of 
BF individuals, allowing them to maximize energy intake 
from dietary fiber, and protecting against inflammation and 
noninfectious colonic disease. They also suggested a poten-
tial impact of the “Western diet” on the colonization and 
establishment of the intestinal microbiota in European and 
other developed countries.
Similar adaptation of microbiota to a specific diet 
was demonstrated in the gut microbiome of Japanese 
individuals, which is the only microbiome to date shown to 
possess the porphyranase genes. Hehemann et al. [37] sug-
gested that those enzymes, which are involved in the carbo-
hydrate metabolic pathway of porphyran from marine red 
algae, were most likely acquired by the human gut microbi-
ota through horizontal gene transfer from marine microbes. 
These results are concordant with the fact that Japanese 
people have a tradition of eating foods containing raw sea-
weed (such as nori, the edible seaweed of the red algae 
genus Porphyra that is used in preparing sushi) and this is 
suggested as the reason for the presence of porphyranases 
in Japanese but not American gut microbiota [37, 38].
Another example of when long-term dietary practices 
affect the composition of the resident microbiota was dem-
onstrated for developed countries and the so-called West-
ern diet, which is high in sugar and fat. This diet can cause 
dysbiosis by increasing the number of Clostridium innoc-
uum, Eubacterium dolichum, Catenibacterium mitsuokai 
and Enterococcus spp. and decreasing Bifidobacteria and 
Bacteroidetes [9, 39, 40]. Wu et al. [41] showed that the 
Bacteroides enterotype was highly associated with a diet 
rich in animal protein, particular types of amino acids and 
saturated fats, which suggests that meat consumption (as in 
a Western diet) characterized this enterotype. In contrast, 
the Prevotella enterotype was associated with high values 
for carbohydrates and simple sugars, indicating association 
with a carbohydrate-based diet more typical of agrarian 
societies. These results confirmed conclusions from a previ-
ous study, in which overweight adolescents were subjected 
to a calorie-restricted diet (10–40 %) and increased physi-
cal activity (15–23 kcal/kg body weight/wk) over 10 weeks 
[42]. The intervention led to increased numbers of B. fragi-
lis and Lactobacillus groups, and decreased numbers of the 
Clostridium coccoides group, Bifidobacterium longum and 
B. adolescentis. The role of changes in gut composition in 
the development of obesity was examined in an Egyptian 
population [43]. The results confirmed that the numbers of 
bacteria from the phyla Firmicutes and Bacteroidetes were 
statistically significantly increased in the obese group com-
pared with the normal weight group. Moreover, a trend for 
subjects with high fat intake to have positive Firmicutes, 
and those with the highest carbohydrate intake to have pos-
itive Bacteroidetes and Firmicutes, was also observed.
Vegetarianism is a diet that can modulate the intesti-
nal microbiota in humans because of the high amounts of 
fiber consumed. It results in increased SCFA production by 
microbes [44], which can decrease intestinal pH. Indeed, 
subjects on a vegan or vegetarian diet showed significantly 
lower intestinal and stool pH, which prevented the growth 
of potentially pathogenic bacteria such as E. coli and other 
members of the Enterobacteriaceae [45]. Significantly 
lower total counts of Bacteroides spp., Bifidobacterium 
spp., E. coli and Enterobacteriaceae spp. in vegan samples 
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was demonstrated compared with controls. Enrichment of 
Prevotella versus Bacteroides was also shown for vegetar-
ians as well as for individuals who consume a high propor-
tion of fruit and vegetables and a low proportion of meat. 
The reverse was associated with a diet that contains a low 
proportion of plant-based foods [25, 41]. Dietary interven-
tions designed to promote SCFA production in the colon 
may therefore have some efficacy in the treatment of 
dysbiosis.
Impact of diet‑derived nutraceuticals on the microbiota
Polyphenols
Many studies have examined the potential effects of poly-
phenols against pathogens. However, there are notably few 
studies investigating the influence of polyphenols on the 
composition and activity of the nonpathogenic gut micro-
bial community. The most potent inhibitors of microorgan-
ism growth are probably the polyphenolic compounds from 
green and black tea. It has been shown that the bioactive 
components of tea, which include epigallocatechin gallate, 
epicatechin gallate, epigallocatechin, gallocatechin, epi-
catechin and catechin [46], can inhibit the growth of many 
pathogens including Helicobacter pylori [47], Staphylococ-
cus aureus, E. coli O157:H7 [48, 49], Salmonella typhimu-
rium DT104, Listeria monocytogenes, methicillin-resistant 
S. aureus [50, 51], Pseudomonas aeruginosa [52], hepatitis 
C virus [53], influenza virus [54], HIV [55–57], Epstein–
Barr virus [53] and fungi of the Candida genus [58]. Some 
studies suggest that polyphenols can stimulate the growth 
of commensal and beneficial microbiota while pathogenic 
strains are inhibited. For example, the growth of certain 
pathogenic bacteria such as Clostridium perfringens, C. 
difficile and Bacteroides spp. was significantly inhibited by 
tea phenolics and their derivatives, while commensal anaer-
obes such as Clostridium spp., Bifidobacterium spp. and 
probiotics such as Lactobacillus spp. were less severely 
affected [59].
The inhibitory effect of citrus polyphenols such as hes-
peretin, naringenin, poncirin and diosmetin on the growth 
of H. pylori [60] has also been demonstrated. Parkar et al. 
[61] investigated the effect of common dietary polyphe-
nols on the growth of the human gut bacteria and their 
adhesion to enterocytes. All of the polyphenols analyzed, 
except rutin, were found to affect the viability of represent-
ative gut microflora in vitro at doses likely to be present 
in the gastrointestinal tract, but to different degrees. Nar-
ingenin and quercetin were the most active with the low-
est minimum inhibitory concentrations for all of the four 
bacteria tested (Lactobacillus rhamnosus, E. coli, S. aureus 
and S. typhimurium). Naringenin and phloridzin were the 
most effective inhibitors of S. typhimurium adherence to 
Caco-2 enterocytes, while phloridzin and rutin enhanced 
the adherence of the probiotic L. rhamnosus. Polyphenols 
thus appear to be able to alter gut microecology and, by 
affecting the total number of beneficial species in the gut, 
may confer positive gut health benefits. In another study, 
it was demonstrated that both rutin and quercetin inhibited 
the growth of the pathogenic bacteria E. coli and Serratia 
marcescens, while only quercetin had an inhibitory impact 
on Klebsiella pneumonia and Proteus vulgaris [62]. Differ-
ences between the actions of polyphenols belonging to the 
same group (flavonols or flavanones) are probably depend-
ent on the 4-carbonyl group in the C ring of the flavonoid 
skeleton. The results of Duda-Chodak [31] suggest that the 
presence of this group is critical for the inhibitory activity 
of flavonols and flavanone aglycones. It was demonstrated 
that flavonoid aglycones (at doses 4–250 μg/ml), but not 
their glycosides, may inhibit growth of some intestinal bac-
teria. In this study, rutin had no inhibitory influence on the 
intestinal bacteria analyzed, and even slight stimulation of 
the growth of Lactobacillus spp. was observed. In contrast, 
its aglycone quercetin exerted a dose-depended inhibi-
tory effect (except on Bifidobacterium catenulatum), and 
this was especially strong on Ruminococcus gauvreauii, 
Bacteroides galacturonicus and Lactobacillus spp. (MIC 
20–50 μg/ml) growth. The same was true for flavanones. 
Naringin and hesperidin (flavanone glycosides) had no 
impact, but their aglycones (naringenin and hesperetin, 
respectively) inhibited growth of almost all bacteria ana-
lyzed (MIC ≥ 250 μg/ml). In the same study, catechin had 
no influence on tested representatives of human intestinal 
microbiota. (+)-Catechin has been shown to significantly 
inhibit growth of Clostridium histolyticum [63]; however, 
the impact of catechin on Clostridium depends on the spe-
cies. In cultures with (+)-catechin, statistically significant 
increases in the growth of the C. coccoides–Eubacterium 
rectale group, Bifidobacterium spp. and E. coli, as well as 
a significant inhibitory effect on the growth of the C. his-
tolyticum group, have been shown [63]. The significant 
changes in bacterial composition in response to (+)-cate-
chin were accompanied by its rapid conversion to (+)-epi-
catechin. In contrast, the effect of (–)-epicatechin was less 
profound, only significantly increasing the growth of the C. 
coccoides–E. rectale group.
The growth of Clostridium spp. can be decreased sig-
nificantly by a tannin-rich diet or red wine polyphenols, 
while Bacteroides and Lactobacillus will be stimulated in 
such conditions [64, 65]. In the study of Sanchez-Patan 
et al. [66], an extract of wine phenolics (rich in quercetin, 
flavan-3-ols and anthocyanins) had no influence on the 
Lactobacillus/Enterococcus spp., Bacteroides spp., Bifido-
bacterium spp. and members of the domain bacteria. An 
observed slight inhibition in the C. histolyticum group was 
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not significant. However, red wine polyphenols can influ-
ence the gut microbiota. The daily consumption of red wine 
polyphenols for 4 weeks significantly increased the number 
of Enterococcus, Prevotella, Bacteroides, Bifidobacterium, 
Bacteroides uniformis, Eggerthella lenta and Blautia coc-
coides–E. rectale groups [67].
Flavonols can also modulate the gut microbiota by 
affecting the adhesion of bacteria to intestinal cells, but 
the influence of flavan-3-ols on bacterial adhesion differs 
greatly between compounds, strains and degree of differ-
entiation of intestinal cells [68]. All flavan-3-ols tested sig-
nificantly inhibited adhesion of Lactobacillus acidophilus 
LA-5 and Lactobacillus plantarum IFPL379, except epi-
gallocatechin gallate, which enhanced L. acidophilus LA-5 
adhesion to Caco-2 cells. Procyanidins B1 and B2 mark-
edly increased the adhesion of Lactobacillus casei LC115 
to HT-29 cells, whereas epigallocatechin increased L. casei 
LC115 adhesion to Caco-2 cells.
There are only a few studies that have examined the 
antibacterial properties of anthocyanins. The anthocya-
nidins pelargonidin, delphinidin and cyanidin, as well as 
cyanidin-3-glucoside (C3G), have been shown to inhibit 
growth of E. coli CM 871, but had no effect on strains of 
the Lactobacillus and Bifidobacterium genera, Salmonella 
enterica SH-5014 or Enterococcus faecalis E-203 [69]. It 
was also found that C3G inhibited secretion of CagA and 
VacA in H. pylori via down-regulation of secA expression 
[70]. This means that a diet abundant in various berries 
rich in C3G may be beneficial in reducing gastric inflam-
mation or stomach cancer if these are dependent on H. 
pylori infection. In another study, all of the anthocyanins 
tested significantly enhanced the growth of Bifidobacterium 
spp. and Lactobacillus–Enterococcus spp., suggesting that 
anthocyanins and their metabolites may exert a positive 
effect on the intestinal bacterial population [71].
Anthocyanins have been shown to stimulate the growth 
of lactic acid bacteria and increase malolactic fermenta-
tion [72]. These bacteria can cleave the anthocyanin mol-
ecules and use the sugar moiety as a carbohydrate source. 
Cranberries, a fruit rich in proanthocyanidins, are used for 
maintaining urinary tract health. It is thought that the ben-
eficial effect of cranberry is due to antiadhesion activity 
against both antibiotic-susceptible and antibiotic-resistant 
strains of uropathogenic P-fimbriated E. coli [73]. It has 
been shown that cranberry proanthocyanidins have unu-
sual A-type linkages [74] compared with the more com-
mon B-type linkages found in proanthocyanidins from 
other tannin-rich foods. Howell et al. [75] postulated 
that this is the reason why cranberry consumption pre-
vents urinary tract infections while other foods contain-
ing only B-linked proanthocyanidin do not. There are 
no data to date on the antiadhesion activity of B-linked 
proanthocyanidins.
All of the results described above confirm that polyphe-
nols can modulate the composition of the intestinal micro-
biota and hence indirectly influence their own metabolism 
and bioavailability.
Prebiotics
Diets abundant in plant polysaccharides contain resistant 
starch and oligosaccharides that undergo bacterial fermen-
tation in the intestine. Indigestible by the host, complex 
polysaccharides are converted by the primary degrader 
bacteria resulting in the release of a wide range of SCFAs 
(mainly acetate, propionate and butyrate) and a number 
of other metabolites (lactate, pyruvate, ethanol, succinate, 
soluble oligosaccharides, gases) that are the “fuel” for sec-
ondary degrader bacteria [76–78]. Changes in the intestinal 
microbiota observed in individuals that switch to a GFD 
can be explained by the reduction in polysaccharide intake. 
High intake of dietary fiber results in a greater SCFA con-
centration and lower E. coli counts in mammalian intes-
tine, while an opposite trend has been shown with low fiber 
intake [33].
Bacterial fermentation products can be used as nutrients, 
as well as growth signals for the intestinal epithelium. For 
example, butyrate (which has prodifferentiation, antiprolif-
eration and antiangiogenic effects on colonocytes [79]) is 
utilized by those cells as a major energy substrate; acetate 
is mainly metabolized in human muscle, kidney, heart and 
brain; and propionate is cleared by the liver [80].
A nondigestible food ingredient that beneficially affects 
the host by selectively stimulating the growth and/or activ-
ity of one or a limited number of bacteria in the colon, and 
thus improves host health, is called a prebiotic [81]. A more 
recent definition of a prebiotic is “a selectively fermented 
ingredient that allows specific changes, both in the compo-
sition and/or activity in the gastrointestinal microflora, that 
confer benefits upon host well-being and health” [82]. In 
order for a food ingredient to be classified as a prebiotic, 
it must satisfy four criteria: (1) be neither hydrolyzed nor 
absorbed in the upper part of the gastrointestinal tract; (2) 
be a selective substrate for one or a limited number of ben-
eficial bacteria commensal to the colon, which are stimu-
lated to grow and/or are metabolically activated; (3) con-
sequently, be able to alter the colonic flora in favor of a 
healthier composition; and (4) induce luminal or systemic 
effects that are beneficial to the host’s health. Among the 
food ingredients, nondigestible carbohydrates (oligo- and 
polysaccharides), some peptides and proteins, and certain 
lipids (both ethers and esters) are candidate prebiotics. 
Because of their chemical structure, these compounds are 
not absorbed in the upper part of the gastrointestinal tract 
nor hydrolyzed by human digestive enzymes. Nondigest-
ible lipids that naturally occur in the diet have not yet been 
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examined in this context, and their metabolism and benefi-
cial effect on host health is still theoretical. In the case of 
proteins that reach the colon, their anaerobic proteolysis 
generates a range of metabolites including the branched-
chain fatty acids such as isobutyrate, isovalerate and iso-
caproate, as well as indoles, phenolic compounds, sulfides, 
ammonium, histamine and oxaloacetate. These putrefactive 
products are generally considered to be toxic and to cause 
adverse effects on the colonic epithelium [81, 82], so pro-
teins are not considered viable as prebiotics. Most prom-
ising prebiotics are nondigestible oligosaccharides, includ-
ing fructooligosaccharides, galactooligosaccharides (GOS) 
and inulin. Trans-galactooligosaccharides are a mixture 
of oligosaccharides derived from the enzymatic transgly-
cosylation of lactose. The selective growth stimulation of 
Bifidobacterium and Lactobacillus by GOS has been shown 
[83–86] along with a significant decrease in the concentra-
tion of Bacteroides, Candida [83] and Enterobacteriaceae 
[84]. Lactulose, which is one of the best characterized 
prebiotic components produced by the isomerization of 
lactose, selectively stimulated growth of Bifidobacterium, 
Lactobacillus and Streptococcus, whereas numbers of C. 
perfringens, Bacteroides and Enterobacteriaceae were 
reduced [82].
Supplementation of fecal specimens with lactulose and 
blood decreased toxic short-chain (iC4-nC6) fatty acid 
(isobutyrate, butyrate, isovalerate, valerate, isocaproate 
and caproate) production and increased acetate and lac-
tate production, resulting in increased fecal acidity. These 
changes were statistically significant when compared with 
supplementation with blood alone and correlated with the 
reduction in the growth of C. difficile and Bacteroides 
spp. [87].
Inulins are common plant storage carbohydrates that 
are nutritionally classified as dietary fibers. Inulin-type 
fructans are present in a range of different plants includ-
ing wheat, onion, banana, garlic, leek and Agave tequilana 
[80]. Numerous in vitro and in vivo studies have demon-
strated that inulin and oligofructose selectively stimulate 
the health-promoting groups of human intestinal microbi-
ota, Bifidobacterium and Lactobacilli [88]. Administration 
of inulin and oligofructose, either alone or as a synbiotic, 
has been shown to selectively increase numbers of bifido-
bacteria in the luminal and mucosa-associated microbiota, 
typically representing a prebiotic effect [88–90]. Both in 
vitro and in vivo studies have demonstrated that the colonic 
fermentation of inulin-type fructans increases the produc-
tion of butyrate, which is the so-called butyrogenic effect. 
This can be explained by bacterial cross-feeding; i.e., lac-
tate produced by Bifidobacterium adolescentis is converted 
to butyrate by Eubacterium hallii and Anaerostipes cac-
cae (both Firmicutes). The latter bacterium can also utilize 
released fructose monomers to produce butyrate [91, 92].
Polyunsaturated fatty acids
Polyunsaturated fatty acids (PUFAs) include, among oth-
ers, the ω-3 fatty acids (linolenic, eicosapentaenoic and 
docosahexaenoic acids) and ω-6 fatty acids (linoleic and 
arachidonic acids). Some interactions of PUFAs with 
the gut microbiota or with certain probiotics have been 
reported. In vitro studies on the effects of free linoleic, 
γ-linolenic, arachidonic, α-linolenic and docosahexaenoic 
acids at concentrations of 10–40 μg/ml demonstrated the 
inhibition of growth and mucus adhesion of the probiotics 
L. rhamnosus GG and L. casei Shirota as well as Lactoba-
cillus delbrueckii subsp. bulgaricus (dairy strain). PUFAs 
also altered bacterial adhesion sites on Caco-2 cells [93]. 
In contrast, when linoleic acid and α-linolenic acid were 
added to medium with various Bifidobacterium species, 
their conversion to conjugated linoleic acid (CLA) and con-
jugated linolenic acid isomers, respectively, started imme-
diately [94]. There is growing interest in CLA because both 
beneficial and detrimental effects for human health have 
been reported [95, 96].
Diet‑derived bioactive metabolites produced by gut 
microbiota and their potential impact on human health
The intestinal microbiota is equipped with a large set of 
different enzymes capable of various modifications of food 
ingredients that enter the colon. It can hydrolyze glyco-
sides, glucuronides, sulfates, amides, esters and lactones 
through the action of enzymes such as α-rhamnosidase, 
β-glucuronidase, β-glucosidase, sulfatase and esterases. 
Other reactions catalyzed by the gut microbial enzymes 
are aromatic ring cleavage, reductions (reductases, hydro-
genases), decarboxylation (decarboxylase), demethylation 
(demethylase), isomerization (isomerase) and dehydroxyla-
tion (dehydroxylase) [97, 98]. This large and diverse enzy-
matic capacity generates various metabolites that have both 
beneficial and detrimental effects on the host. In addition to 
the previously mentioned SCFAs, the gut microflora thus 
generates many important bioactive metabolites.
Polyphenols
A vegetarian diet is abundant in polyphenols and antioxi-
dants, which are secondary plant metabolites with many 
important properties such as anti-inflammatory, antimicro-
bial, antiradical and anticancer activity [99, 100]. It has 
also been shown that anthocyanins, important compounds 
present in various types of berries, can promote urinary 
tract and dermal health, as well as exhibiting anticancer, 
antioxidant, neuroprotective, cardioprotective and antidia-
betic properties [101, 102]. The bioavailability and impact 
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of polyphenols on the host greatly depend on their trans-
formation by specific components of the gut microbiota via 
esterase, glucosidase, demethylation, dehydroxylation and 
decarboxylation activities [97].
Owing to the great diversity of species forming the 
intestinal microbiota in different individuals, the profile of 
polyphenol metabolites that are generated and their final 
effect on the body are highly variable within the human 
population. In many situations, only a product of bacterial 
metabolism of a polyphenol can be absorbed and exert a 
beneficial impact in humans. A lack of particular species 
within the microbiota may mean that a polyphenol cannot 
exert its expected effect even though it has been consumed.
One of the better-characterized types of polyphenol 
metabolites are the nonsteroidal estrogens. Some intes-
tinal bacteria, such as Eggerthella spp. strain YY7918, 
Eggerthella spp. Julong 732, Enterococcus faecium, Adler-
creutzia equolifaciens, Slackia equolifaciens, Lactobacil-
lus mucosae, Bifidobacterium spp., Slackia isoflavoni-
convertens and Bacteroides ovatus [103–109], are able to 
metabolize the soya isoflavone daidzein to equol and/
or O-desmethylangolensin (O-DMA). The prevalence of 
equol producers and O-DMA producers is approximately 
30–50 and 80–90 %, respectively [108–110], and the rate 
of equol formation is influenced by dietary habits, food 
matrix, composition of the intestinal microflora, extent of 
intestinal bacterial fermentation, intestinal transit time and 
alterations in the redox level in the large intestine [111]. 
The metabolic pathways of daidzein degradation by bacte-
ria are presented in Fig. 1.
Equol exerts many different effects, the most important 
being endocrine. Its high binding affinity to the estrogen 
receptor (S-equol preferentially activates ERβ) [108, 109, 
112] has been used to alleviate the symptoms of meno-
pause [107]. Antiandrogenic effects and inhibition of osteo-
clast formation have also been observed [113–115]. In vitro 
studies have revealed anticancer activities, mainly due to 
the inhibition of cancer cell migration and invasion, as well 
as induction of apoptosis in cancer cells [116, 117]. Anti-
inflammatory effects are the results of iNOS inhibition and 
eNOS activation [118]. Other ligands for estrogen receptors 
are enterolactone, enterodiol, urolithin A and 8-prenylnar-
ingenin. These are polyphenol metabolites generated by 
various bacteria, e.g., Bacteroides spp., Clostridium spp., 
Eubacterium limosum and E. lenta [119–121]. Enterolac-
tone and enterodiol are lignan derivatives of polyphenols 
from sesame seed or flaxseed, urolithin A is a metabolite 
of ellagitannins from various berries, while 8-prenylnarin-
genin is generated from isoxanthohumol present in hops 
(Fig. 2). All of these can bind to estrogen receptors and 
inhibit cancer development by the inhibition of cancer pro-
liferation, invasion and angiogenesis [121–123].
Some polyphenols and products of their metabolism 
have a negative effect. For example, owing to metabolism 
by intestinal bacteria, quercetin and rutin can be trans-
formed to 3,4-dihydrophenylacetic acid (DOPAC) (Fig. 3), 
which is a metabolite of the neurotransmitter dopamine. It 
has been demonstrated that DOPAC has anticancer, anti-
inflammatory, cardioprotective and neuroprotective proper-
ties. However, in the presence of the NO radical, DOPAC 
inhibits mitochondrial respiration in isolated brain mito-
chondria, leading to mitochondrial dysfunction, which 
might be an important mechanism involved in the neurode-
generation associated with Parkinson’s disease [124–126].
Fig. 1  Proposed pathways of bacterial metabolism of daidzin and daidzein (based on [16, 103, 111]) (color figure online)
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Procyanidins, oligomers of flavan-3-ols, are present in 
many fruits, especially in berries, wine, tea and nuts. They 
can be metabolized by intestinal bacteria to 3,4-dihydroxy-
phenylvaleric acid, which can be further degraded into phe-
nolic acids such as 3,4-dihydroxyphenylpropionic (dihy-
drocaffeic acid) and 3,4-benzoic acids. However, recent 
studies have postulated that α-oxidation of 3,4-dihydroxy-
phenylvaleric acid can lead to 3,4-dihydroxyphenylacetic 
acid formation, which means that this compound can be 
released from both monomeric and dimeric flavonols (pro-
cyanidin) [127].
Excessive intake of many polyphenolic compounds 
seems to exert an adverse effect on the body [128]. First 
of all, in the presence of O2 and transition metals (Cu, Fe), 
some polyphenols may act as pro-oxidants, leading to dam-
age of DNA, lipids and other biological molecules. This 
pro-oxidant activity can be applied for cancer therapy and 
has a beneficial impact on the host cell, but if uncontrolled, 
the effect will be detrimental. Moreover, flavonoids can 
change the activity of phase I and II metabolizing enzymes, 
such as cytochrome P450 (CYP), P-form phenol sul-
fotransferase, glutathione S-transferase, NAD(P)H:quinone 
oxidoreductase and UDP-glucuronyl transferase. This 
inhibitory/stimulatory activity of particular polyphenols 
is utilized in cancer therapy [128]. However, it has been 
observed that simultaneous administration of flavonoids 
and clinically used drugs may cause flavonoid–drug inter-
actions. Such interactions, by modulating the pharmacoki-
netics of the drugs, can increase their toxicity or diminish 
their therapeutic effect, depending on the flavonoid struc-
ture [128]. Naringenin, a major flavanone present in grape-
fruit juice, exerts an inhibitory effect on intestinal CYP3A4 
within 30 min. This means that the metabolism of certain 
drugs, such as those belonging to calcium channel antago-
nist or immunosuppressant groups (e.g., felodipine, nitren-
dipine, nicardipine, amlodipine, nisoldipine, verapamil, 
terfenadine, cyclosporine, midazolam, triazolam), would be 
impaired if they were co-administered with grapefruit juice 
[129].
The bioactive properties of polyphenol metabolites can 
be completely different from the activity of the parent com-
pounds. There are approximately 700 anthocyanins isolated 
from plants, but the most commonly known are based on 
six anthocyanidins: cyanidin, delphinidin, pelargonidin, 
peonidin, petunidin and malvidin [130, 131]. The majority 
of dietary anthocyanins are not absorbed in the upper parts 
of the gastrointestinal tract, so they reach the colon and are 
metabolized by intestinal microbiota, resulting in the gener-
ation of new compounds, which may be absorbed and thus 
have an impact on both the microbiota and the host. The 
Fig. 2  Ligands for estrogen receptors generated by the intestinal microbiota: a urolithin A; b 8-prenylnaringenin; and c enterolactone and enter-
odiol (based on 16, 97, 120) (color figure online)
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bacterial catabolism of anthocyanins involves the cleavage 
of 3-glycosidic linkages by bacterial β-glucosidase, which 
causes instability of the anthocyanidin at neutral pH and 
rapid breakdown of the heterocyclic ring. The major stable 
products of degradation are corresponding phenolic acids 
(derived from the B-ring of the anthocyanin skeleton) and 
phloroglucinol derivatives (from A-ring) [131, 132].
The main phenolic acids found as the colonic metabo-
lites of various anthocyanins are protocatechuic, gallic, 
syringic, p-coumaric and vanillic acids [131]. The other 
products of anthocyanin degradation by intestinal micro-
biota are 2,4-dihydroxybenzoic acid and 2,4,6-trihydroxy-
benzoic acid, which have been detected in in vitro studies 
[133].
Protocatechuic acid (PCA) is one of the main bacte-
rial metabolites of complex polyphenols such as antho-
cyanins and procyanidins that are normally found at high 
concentrations in vegetables and fruit [134]. Available 
results support the concept that PCA can exert a variety 
of biological effects by acting on different molecular tar-
gets. It has been shown that PCA possesses antioxidant, 
anti-inflammatory, antihyperglycemic and neuroprotective 
activities and may thus have a preventative role in vari-
ous diseases. Moreover, it inhibits in vitro carcinogenesis 
and exerts proapoptotic and antiproliferative effects in dif-
ferent tissues [135], inhibits monocyte adhesion to tumor 
necrosis factor-alpha-activated mouse aortic endothelium, 
exerts an antiatherogenic effect and decreases cholesterol 
levels [136–139]. The anthocyanin microbial catabolites, 
such as gallic acid, 3-O-methyl-gallic acid and 2,4,6-tri-
hydroxybenzaldehyde, have been tested for their ability to 
induce apoptosis and inhibit cell proliferation in a colon 
cancer model using Caco-2 cells. All of these compounds 
reduced cell proliferation without being cytotoxic and were 
more effective than the parent anthocyanins [140]. Other 
anthocyanin degradation products, 3′-hydroxyphenylacetic 
acid, 3′,4′-dihydroxyphenylacetic acid and 3′-methoxy-
4′-hydroxyphenylacetic acid, inhibited the formation of 
Fig. 3  Possible pathways of the transformation of quercetin and its glycosides due to metabolism by intestinal bacteria (based on [16, 138, 156, 
157]) (color figure online)
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advanced glycation end-products and were effective in pre-
serving cultivated neuron cells from death due to oxidative 
stress [141].
Anaerobic bacteria such as Bacteroides distasonis, 
B. uniformis and B. ovatus can release aglycone from 
quercetin glycosides owing to their β-glucosidase activity 
[138]. Enterobacteria also decompose quercetin aglycone 
to produce its ring scission products such as 3,4-dihy-
droxyphenylacetic acid, m-hydroxyphenylacetic acid and 
m-homovanillic acid [139]. The aglycone is converted to its 
conjugated metabolites with or without O-methylation and 
then transferred to the liver through the portal vein. Some 
conjugated metabolites are likely to be transferred into the 
systemic circulation via lymph. Quercetin glucuronides 
are another kind of quercetin metabolite in humans, and 
their plasma concentration as well as biological activity 
depends on the conjugation position. Day et al. [142] dem-
onstrated that the 5-position did not appear to be a site for 
quercetin conjugation. The K(i) for the inhibition of xan-
thine oxidase by quercetin glucuronides followed the order 
4′- > 3′- > 7- > 3-, with quercetin-4′-glucuronide a particu-
larly potent inhibitor. The glucuronides, with the exception 
of quercetin-3-glucuronide, were also inhibitors of lipoxy-
genase. It was demonstrated that quercetin metabolites are 
likely to exert their physiological function at the target sites 
where they concentrate. It is highly probable that conju-
gated metabolites of quercetin circulate as nontoxic forms 
in the bloodstream, but are later converted to active agly-
cones to exert their function immediately. This effect was 
observed by Kawai et al. [143]. In vitro experiments using 
murine macrophage cell lines showed that quercetin-3-glu-
curonide (Q3GA) was taken up in significant quantities and 
deconjugated into the much more active aglycone, a part 
of which was further converted to the methylated form, in 
activated macrophages. Q3GA accumulated only in athero-
sclerotic lesions but not in normal aorta [143].
Vitamins
The microbiota is involved in the production and absorp-
tion of essential vitamins and micronutrients. The increased 
concentration of SCFAs, which is a final result of bacte-
ria’s metabolism of resistant starch and oligosaccharide, 
may help in the absorption of minerals such as calcium, by 
increasing their solubility and increasing the expression of 
calcium binding proteins [144]. Many studies have shown 
that resistant carbohydrate can be utilized by the intesti-
nal bacteria for folate biosynthesis. The main producers of 
folate are Bifidobacterium bifidum and B. longum subsp. 
infantis [145], Lactococcus lactis subsp. lactis, Streptococ-
cus thermophilus [146], B. adolescentis, B. pseudocatenu-
latum [147] and L. plantarum [148]. A number of other 
B-group vitamins are synthesized by members of the gut 
microbiota, such as thiamine, riboflavin, niacin, pantoth-
enic acid, pyridoxine, biotin and vitamin B12 [145, 149]. 
There are also some studies that indicate a role of the intes-
tinal microbiota in menaquinone (vitamin K2) production 
in the human gastrointestinal tract. Major vitamin K pro-
ducers are species from the Bacteroides genus, E. coli, as 
well as some strains of K. pneumoniae, Propionibacterium 
and Eubacterium species [150]. A negative correlation 
between a low-fiber diet and the abundance of menaqui-
none-producing bacteria in the gut has been demonstrated 
[151].
Among other important bioactive compounds produced 
by the intestinal microbiota are bacteriocins, factors that 
inhibit the growth of pathogenic bacteria. Bacteriocin-pro-
ducing strains of the Pediococcus and Lactococcus genera 
have been isolated from human intestine [152]. It has also 
been shown that human isolates of Pediococcus acidilact-
ici-producing pediocin PA-1 and L. lactis-producing nisin 
Z are able to reduce intestinal colonization by vancomycin-
resistant enterococci in a mouse model [153]. Moreover, L. 
lactis and P. acidilactici administration increased the total 
number of lactic acid bacteria and anaerobes, while P. aci-
dilactici decreased the Enterobacteriaceae population.
Conclusions
For many years, the perception of the function of the large 
intestine was that it was limited to the reabsorption of water 
and salt and the removal of unused food debris, completely 
ignoring the microbiota present. Currently, it is known 
that a large number of bacteria inhabiting the large intes-
tine form a very complex ecosystem called the ‘intestinal 
microbiome’. The intestinal microbiome plays an impor-
tant, possibly crucial, role in the metabolism of chemical 
compounds found in foods. It is estimated that its meta-
bolic capacity is approximately 100-fold greater than the 
capacity of the liver, because of the great diversity of bac-
terial species forming the population, and hence the large 
number of genes that they contain [4]. Moreover, the enor-
mous total number of microorganisms that inhabit the large 
intestine has considerable influence. There are approxi-
mately 1012 bacteria per gram of colonic content, which is 
the highest accumulation of microorganisms that has ever 
been noted in any environment [13].
Owing to the multitude of direct and indirect interac-
tions with the host organism, the intestinal microbiome is 
closely linked to the health of the host [15]. The microbi-
ota plays a protective role by occupying intestinal surfaces 
and creating a milieu that prevents the invasion of patho-
gens (e.g., by production of bacteriocins and other antimi-
crobial compounds). Moreover, the metabolism of those 
bacteria enables the breakdown of indigestible compounds 
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such as resistant starch and plant polysaccharides during 
anaerobic fermentation, which results in SCFA produc-
tion. Other examples of bacterial metabolism are vitamin 
and amino acid synthesis [14]. These metabolites can then 
serve as growth signals and nourishment for the intesti-
nal epithelium of the host, as well as for other microor-
ganisms. Furthermore, the etiology of many diseases is 
largely correlated with the intestinal microbiome or certain 
microbial members. A balance between the host immune 
system and the commensal gut microbiota is crucial for 
maintaining health. If this balance is disturbed (dysbio-
sis), the host–microbe relationship can progress toward a 
disease state [14, 25]. Recent studies suggest that specific 
members of the gut microbiota play a functional role in 
inflammatory bowel disease (including Crohn’s disease), 
colorectal cancers, obesity and allergies [4, 14, 15, 22, 28, 
97, 154, 155].
Over the course of evolution, the human organism has 
developed tools indispensable for the utilization of sug-
ars, lipids and proteins. Despite this, many of these com-
pounds enter further segments of the gastrointestinal tract 
undigested (intact), where they interact with the intesti-
nal microbiota. Bacteria use these compounds as a source 
of energy and nutrients via their own enzymes, some of 
which cannot be produced by human tissues. It should be 
remembered that many of these substances have antibacte-
rial properties. This enables the elimination of pathogens, 
but may have also a detrimental effect due to elimination 
of beneficial microflora. Typically, xenobiotics undergo 
biotransformation processes via the intestinal bacteria, 
which are necessary for their detoxification. The potential 
of the intestinal microbiome for detoxification or bioacti-
vation of xenobiotics is much higher than that of the liver 
and includes other types of reactions not found in the liver. 
Hepatic metabolism is based on the reactions of oxida-
tion and conjugation, mainly resulting in the generation of 
hydrophilic high molecular weight metabolites. Bacterial 
metabolism occurs under anaerobic conditions and is based 
mainly on reduction and hydrolysis reactions, resulting in 
nonpolar low molecular weight products. Therefore, bacte-
rial metabolites are different from those that can be gen-
erated by human enzymes, and their impact on both host 
health and intestinal microbiota thus differs.
Bacterial metabolism usually reduces the activity of die-
tary compounds such as polyphenols, but sometimes a spe-
cific product of bacterial transformation exhibits enhanced 
properties. The products of bacterial metabolism may 
exhibit enhanced or more beneficial effects, or they may 
be degraded to inactive or toxic compounds. Studies on the 
metabolism of polyphenols by the intestinal microbiota are 
therefore crucial for understanding the role of these com-
pounds and their effects on our health.
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